Infinzi for cholangiocarcinoma – pro
NCCN recently added darvulumab to it’s ecmmendation. NCCN recommended as “Other REcommended Regimns”.TOPAZ-1 study reported in FEbruary of 2022, , found that adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy modestly extended how long people with advanced biliary tract cancer lived. TOPAZ-1 is the first large clinical trial to show that initial, or first-line, treatment that includes immunotherapy can improve survival in patients with advanced biliary cancer. In the trial, adding durvalumab to chemotherapy extended the length of time that people were still alive after starting treatment by a median of about 6 weeks compared with people who received chemotherapy plus a placebo. At 2 years after starting treatment on the trial, roughly 25% of patients who received chemotherapy plus durvalumab were still alive, compared with 10% of patients who received chemotherapy plus placebo.
h DY, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. Presented at: 2022 Gastrointestinal Cancers Symposium; January 20-22, 2022; San Francisco, CA. Abstract 378.
Durvalumab significantly improves survival for patients with biliary tract cancer compared to chemotherapy alone. News release. ASCO. January 18, 2022
NCCN Hepatocellular Cancer HCG-1 of 2 2022